We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

53 hedge funds and large institutions have $428M invested in Inozyme Pharma in 2020 Q3 according to their latest regulatory filings, with 53 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

69.77% more ownership

Funds ownership: 0% → 69.77% (+70%)

Holders
53
Holders Change
+53
Holders Change %
–
% of All Funds
1.07%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.06%
New
53
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
+$63.8M
2
NMC
NEA Management Company
Maryland
+$60.7M
3
SI
Sofinnova Investments
California
+$50.4M
4
RCM
RA Capital Management
Massachusetts
+$49.8M
5
DM
Deerfield Management
New York
+$28.6M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
OMC
26
Overbrook Management Corp
New York
$440K +$415K +16,726 New
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$421K +$398K +16,011 New
Goldman Sachs
28
Goldman Sachs
New York
$360K +$340K +13,680 New
Marshall Wace
29
Marshall Wace
United Kingdom
$326K +$308K +12,418 New
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$323K +$305K +12,298 New
SFI
31
Susquehanna Fundamental Investments
Pennsylvania
$288K +$272K +10,955 New
LCM
32
Laurion Capital Management
New York
$269K +$255K +10,250 New
ZP
33
Zimmer Partners
New York
$263K +$248K +10,000 New
MWNA
34
Marshall Wace North America
New York
$250K +$236K +9,514 New
State of Tennessee, Department of Treasury
35
State of Tennessee, Department of Treasury
Tennessee
$238K +$225K +9,044 New
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$223K +$210K +8,469 New
Ensign Peak Advisors
37
Ensign Peak Advisors
Utah
$210K +$198K +7,991 New
Wells Fargo
38
Wells Fargo
California
$161K +$152K +6,113 New
AIG
39
American International Group
New York
$128K +$121K +4,860 New
Deutsche Bank
40
Deutsche Bank
Germany
$116K +$110K +4,430 New
JP Morgan Chase
41
JP Morgan Chase
New York
$72K +$75.2K +3,029 New
CLOS
42
Compagnie Lombard Odier SCmA
Switzerland
$66K +$62.7K +2,525 New
SO
43
STRS Ohio
Ohio
$52K +$49.7K +2,000 New
Morgan Stanley
44
Morgan Stanley
New York
$33K +$31.1K +1,251 New
TRCT
45
Tower Research Capital (TRC)
New York
$33K +$31.3K +1,259 New
Legal & General Group
46
Legal & General Group
United Kingdom
$23K +$22.2K +894 New
AIP
47
Ameritas Investment Partners
Nebraska
$18K +$17.2K +692 New
UBS Group
48
UBS Group
Switzerland
$14K +$13.3K +536 New
Bank of America
49
Bank of America
North Carolina
$12K +$12.1K +487 New
Citigroup
50
Citigroup
New York
$10K +$9.69K +390 New
1
2
3

INZY Hedge Fund Activity: Q3 2020 in Review

53 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2020, worth a combined $428M.

Buyers outnumbered sellers: 53 funds opened new INZY positions and 0 closed out — a net gain of 53 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $63.8M.

  • 53 institutional investors held Inozyme Pharma (INZY) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $428M of Inozyme Pharma stock for Q3 2020.
  • 53 funds opened new Inozyme Pharma positions in Q3 2020 and 0 closed out, a net change of +53 holders.
  • The largest Inozyme Pharma buyer in Q3 2020 was Novo Holdings A/S, an estimated $63.8M added.

Based on aggregated 13F filings for Q3 2020.